What to Know About the No Surprises Act

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jagan Pillai, MD, PhD

Cerebral amyloid angiopathy (CAA) is a common neurological change that frequently coexists with other pathologies like Alzheimer's disease and Lewy body dementia, which led a team of researchers to investigate the risk factors and prevalence of CAA. The study found that not only is age a risk factor for CAA, but CAA is also seen in patients with Lew body pathology alone and in patients with both Alzheimer's disease and Lewy body pathology. Dive further into the findings with Dr. Charles Turck and Dr. Jagan Pillai, a behavioral neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health.

Host: Andrew Wilner, MD, FACP, FAAN
Guest: Marcus E. Peter, PhD

Death induced by survival gene elimination (DISE) is a cell death mechanism mediated by short RNAs. And according to a recent study, there may be a correlation between toxic DISE, DNA damage, and neuronal cell death in patients with Alzheimer’s disease. Learn more about the study’s findings and potential implications with Dr. Andrew Wilner and Dr. Marcus Peter, Professor of Medicine in the Division of Hematology and Oncology as well as a Professor of Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine in Chicago.

Host: Andrew Wilner, MD, FACP, FAAN
Guest: George Bloom, PhD

Toxic tau protein refers to an aberrant form of the tau protein in the brain, commonly associated with Alzheimer's disease, where it forms tangles and disrupts normal cellular function, which contributes to cognitive decline and neuronal damage. To learn more about the role of toxic tau proteins in Alzheimer’s disease, tune in to hear Dr. Andrew Wilner speak with Dr. George Bloom, Professor of Biology, Cell Biology, and Neuroscience at the University of Virginia.

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jini Naidoo, PhD

According to new research featured in Aging Biology, a treatment involving 4-phenylubrate (PBA) may delay or reverse signs of Alzheimer’s disease. To learn more, Dr. Andrew Wilner dives into the results and potential implications of this mouse-model study with Dr. Jini Naidoo, Research Associate Professor of Sleep Medicine at the Perelman School of Medicine at the University of Pennsylvania.

Host: Andrew Wilner, MD, FACP, FAAN
Guest: Marc Haut, PhD

A recent phase 1 study investigated the safety and feasibility of combining focused ultrasound and aducanumab, which is a monoclonal antibody for amyloid, to open the blood-brain barrier in patients with Alzheimer's disease. And what the researchers found was about a 50 percent overall reduction of cerebral amyloid-beta load in the target areas compared to the untreated areas. Dive further into these findings and next steps in this line of research that may impact the way we treat Alzheimer’s disease with Dr. Andrew Wilner and Dr. Marc Haut, Director of the Rockefeller Neuroscience Institute’s Memory Health Clinic at West Virginia University.

Host: Raj Chovatiya, MD, PhD
Guest: Melinda Gooderham, MSc, MD, FRCPC

Due to the evolving treatment landscape, the way we think about treating adult and elderly patients with atopic dermatitis has shifted. So what are some special considerations we need to think about when selecting a treatment option for long-term control, and how can we best involve patients in the decision-making process? Joining Dr. Raj Chovatiya to help answer these and other key questions in atopic dermatitis care is Dr. Melinda Gooderham, Medical Director for the SKiN Center for Dermatology in Peterborough, Ontario.

Guest: Candace T. Westgate, DO, MPH, FACOG
Guest: Ethan D. Schram, MD, FACP

Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25 percent of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-based multi-cancer early detection, or MCED, tests that can screen from four to greater than 50 types of cancers have been developed to complement the population-based screening of asymptomatic individuals. At the spring 2023 American Association for Cancer Research, also known as AACR, American Society of Clinical Oncology, or ASCO, and National Comprehensive Cancer Network, orNCCN, annual conferences, a multitude of data was presented on MCEDs, including real-world data, clinical trial data, novel MCEDs in development, MCED accuracy, and the inherent health equity challenges that their implementation will face. This educational activity has two parts. Dr. Candace Westgate delivers an MCED Primer designed to build primary care clinicians’ knowledge about the science of MCEDs and how to implement their use in primary care practice, followed by chapterized discussions between …

Host: John Buse, MD, PhD
Guest: Anna Kahkoska, MD, PhD

Continuous glucose monitoring (CGM) can help improve glycemic management in patients with type 1 diabetes (T1D), but integrating this technology can be a complex learning process for older adults. So what do we need to consider when it comes to CGM use in older adults? Find out with Dr. John Buse and Dr. Anna Kahkoska, Assistant Professor in the Department of Nutrition and an Adjunct Assistant Professor in the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill. Dr. Kahkoska is also the author of a recent paper, titled “Nothing is linear: Characterizing the determinants and dynamics of CGM use in older adults with type 1 diabetes.”

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lokesh Shahani, MD, PhD, MPH, FACP, FASAM

Due to their clinical overlap, distinguishing between neurocognitive and psychiatric disorders can be challenging, but an accurate diagnosis is crucial for timely assessment and treatment. Find out how we can better identify and treat complex neurocognitive disorders such as Alzheimer's disease and other forms of dementia with Dr. Charles Turck and Dr. Lokesh Shahani, Associate Professor of Psychiatry and Behavioral Sciences at UT Health Houston McGovern Medical School who presented on this exact topic at the 2023 APA Annual Meeting.

Host: Jerome Lisk, MD
Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA

Behavioral and psychological symptoms of dementia (BPSD) refers to a group of noncognitive symptoms that commonly occur in patients with dementia. While data shows efficacy for treatment modalities for these symptoms and behaviors, the use of psychotropic medications has been met with controversy due to their adverse effects. Tune in to hear Dr. Rajesh Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine, discuss how we can address those controversies while providing optimal care for our patients, which was the focus of his presentation at the 2023 American Psychiatric Association Annual Meeting.